alpha aat deficiency genetic disease low serum lung levels antiprotease aat cause deficiency defensive screen lower respiratory tract neutrophil elastase free degrade connective tissue lung eventually resulting emphysema intravenous aat infusion therapy restores lung levels aat inefficient costly demanding form therapy alternative evaluated aerosol delivery human plasma aat paat recombinant aat raat means providing protection lower respiratory tract vitro studies demonstrated paat raat aerosolized droplets suitable alveolar deposition loss antiprotease activity administered aerosol individuals aat deficiency paat raat significantly raised lung epithelial lining fluid levels aat elastase capacity likelihood twice daily administration NUMBER mg form result normalization lung defenses alveolar surface studies sheep demonstrated aerosolized paat raat able pass alveolar epithelium gain access interstitial compartment lung increasing defenses lung interstitium therapy safe tolerated cases aerosol therapy paat raat safe feasible likely biochemically efficacious alternative intravenous aat augmentation therapy merits studies clinical therapy NUMBER antitrypsin anti elastase dna produced anti elastase anti neutrophil anti elastase anti elastase long term